Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20831010 | 0.88 | KMT2A (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL15315001 | 0.86 | TDP1 (0.64) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL10730740 | 0.84 | LMNA (0.64) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL5064633 | 0.83 | MAPT (0.54) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL20830732 | 0.82 | TDP1 (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL20841715 | 0.82 | TDP1 (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL18427933 | 0.82 | KMT2A (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL10323667 | 0.82 | TDP1 (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL20831011 | 0.82 | TDP1 (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL20400956 | 0.82 | KMT2A (0.58) | TDP1KMT2ASLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230011968-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-12 | — | — | US | disclosed |
| EP-3456713-A1 | PROCESS FOR THE PREPARATION OF TRIAZINE DERIVATIVES | Japan Tobacco Inc. (JP) | 2019-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011968-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGIS, PTGS1, PTGES | TDP1 493/4885KMT2A 3785/4885SLC6A2 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.